Use of fibrates in clinical practice: Queensland lipid group consensus recommendations

International Journal of Evidence-Based Healthcare

Volumn 10, Issue 3, 2012, Pages 181-190

  Hamilton Craig, Ian ^a   Kostner, Karam Maximilien ^b   Woodhouse, Stan ^b   Colquhoun, David ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Diabetes mellitus; Fibrates; Macrovascular disease; Microvascular disease; Preventative healthcare; Risk management

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; AUSTRALIA; BLOOD; DIABETES MELLITUS; DRUG COMBINATION; DRUG INTERACTION; HUMAN; HYPERLIPIDEMIA; PRACTICE GUIDELINE;

DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; QUEENSLAND;

EID: 84867974568     PISSN: 17441595     EISSN: 17441609     Source Type: Journal    
DOI: 10.1111/j.1744-1609.2012.00275.x     Document Type: Article

References (59)

1. Streja D, Streja E. Management of dyslipidemia in the elderly. Available from: http://www.endotext.org/aging/aging4/ agingframe4.htm
2. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia - current therapies and future agents. Expert Opin Pharmacother 2003; 4: 1901-38.
3. Alagona P. Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vasc Health Risk Manag 2010; 6: 351-62.
4. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidaemia: a meta-analysis. Atherosclerosis 2011; 217: 492-8.
5. Abourbih S, Filion KB, Joseph L et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med 2009; 122: 962.e1-8.
6. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 2008; 28: 39-46. Epub 2007 Aug 23.
7. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011; 57: 267-72.
8. Rubenfire M, Brook RD, Rosenson RS. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med 2010; 123: 892-8.
9. Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vasc Health Risk Manag 2008; 4: 991-1000.
10. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-19.
11. Patel A, Barzi F, Jamrozik K. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004; 110: 2678-86.
12. Mazza A, Tikhonoff V, Schiavon L, Casiglia E. Triglycerides + high-density-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the Cardiovascular Study in the Elderly. Intern Med J 2005; 35: 604-10.
13. Sarwar N, Danesh J, Eiriksdottir G et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-8.
14. Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011; 123: 2292-333.
15. Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011; 97: 350-6.
16. Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345-61.
17. Abbott Pharmaceuticals Website. Accessed 1 December 2011. Available from: http://www.rxabbott.com
18. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.
19. Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011; 123: 2292-333.
20. Watts GF, Sullivan DR, Poplawski N et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl 2011; 12: 221-263.
21. Product information for fenofibrate. Accessed 1 December 2011. Available from: http://www.rxabbott.com
22. Farnier M, Freeman MW, Macdonell G et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26: 897-905.
23. Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. Combination therapy of statin and ezetimibe for treatment of familial hypercholesterolaemia. Vasc Health Risk Manag 2010; 6: 1023-37.
24. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95: 462-8.
25. Product information for ezetimibe. Accessed 1 December 2011. Available from: http://www.zetia.com/ezetimibe/zetia/hcp/product_information/pi/index.jsp
26. Farnier M, Roth E, Gil-Extremera B et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007; 153: 335.e1-8.
27. Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag 2010; 6: 525-39.
28. Davis TM, Ting R, Best JD et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011; 54: 280-90.
29. Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial. Diabetes Care 2011; 34 (Suppl. 2): S107-8.
30. Kostner K, Gupta S. Niacin: a lipid polypill? Expert Opin Pharmacother 2008; 9: 2911-20.
31. NIH pulls plug on AIM-HIGH trial with niacin. Accessed 3 July 2011. Available from: http://www.theheart.org/article/ 1231453.do
32. A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol with Extended Release Niacin/Laropiprant. HPS2-THRIVE. Accessed 3 July 2011. Available from: http:// clinicaltrials.gov/ct2/show/NCT00461630?term=HPS2+thrive&rank=1
33. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-9.
34. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69: 340-5.
35. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73: 538-44.
36. Schneck DW, Birmingham BK, Zalikowski JA et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004; 75: 455-63.
37. Bergman AJ, Murphy G, Burke J et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004; 44: 1054-62.
38. Pan WJ, Gustavson LE, Achari R et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000; 40: 316-23.
39. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97: 27C-31C. Epub 2006 Jan 25.
40. Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375: 1875-84.
41. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-61.
42. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-97.
43. Robins SJ, Bloomfield HE. Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol 2006; 17: 431-9.
44. Rajamani K, Colman PG, Li LP et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-8.
45. Fazio S, Linton MF. Fenofibrate and risk of minor amputations in diabetes. Lancet 2009; 373: 1740-1.
46. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165: 725-30.
47. Scott R, O'Brien R, Fulcher G et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diebetes (FIELD) study. Diabetes Care 2009; 32: 493-8.
48. The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-44.
49. Klein B. Reduction in risk of progression of diabetic retinopathy. N Engl J Med 2010; 363: 287-8. Epub 2010 Jun 29. DOI: 10.1056/NEJMe1005667, accessed 20 June 2011.
50. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. NICE clinical guideline 73. 2008.
51. Drury PL, Ting R, Zannino D et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011; 54: 32-43.
52. Kostner KM, Cauza E. HDL therapy: the next big step in the treatment of atherosclerosis? Future Cardiol 2005; 1: 767-73.
53. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-10.
54. Tonkin A, Barter P, Best J et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management - 2005. Heart Lung Circ 2005; 14: 275-91.
55. Després JP. Increasing high-density lipoprotein cholesterol: an update on fenofibrate. Am J Cardiol 2001; 88: 30N-6N.
56. Kostner KM, Kostner GM. Fibrate bei Lipidstoffwechselstoerungen. (Fibrate in lipid metabolism disorders). Pharazie Unserer Zeit 2007; 36: 114-19.
57. Goldberg RB, Sabharwal AK. Fish oil in the treatment of dyslipidemia. Curr Opin Endocrinol Diabetes Obes 2008; 15: 167-74.
58. European Medicines Agency press release 22 Oct 2010. Accessed 1 December 2011. Available from: http://www.ema.europa.eu
59. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002; 325: 1139.